LON:ONC - Oncimmune Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 103 +4.50 (+4.57 %) (As of 12/12/2018 08:47 AM ET)Previous CloseGBX 98.50Today's RangeGBX 102 - GBX 10352-Week RangeGBX 100 - GBX 150Volume3,000 shsAverage Volume33,554 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer in the United Kingdom and North America. The company engages in the development of autoantibody assay technologies to allow cancer detection to a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company also develops EarlyCDT tests for liver and ovarian cancer. Oncimmune Holdings Plc was incorporated in 2015 and is based in Nottingham, the United Kingdom. Receive ONC News and Ratings via Email Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolLON:ONC Previous Symbol CUSIPN/A Weboncimmune.com Phone+44-115-8231869 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees52 Outstanding SharesN/AMarket Cap£0.00 OptionableNot Optionable Oncimmune (LON:ONC) Frequently Asked Questions What is Oncimmune's stock symbol? Oncimmune trades on the London Stock Exchange (LON) under the ticker symbol "ONC." How were Oncimmune's earnings last quarter? Oncimmune Holdings PLC (LON:ONC) issued its earnings results on Tuesday, February, 13th. The company reported ($5.70) earnings per share for the quarter. The business earned $0.08 million during the quarter. View Oncimmune's Earnings History. What price target have analysts set for ONC? 2 equities research analysts have issued 12-month price targets for Oncimmune's stock. Their forecasts range from GBX 168 to GBX 169. On average, they expect Oncimmune's share price to reach GBX 168.50 in the next twelve months. This suggests a possible upside of 63.6% from the stock's current price. View Analyst Price Targets for Oncimmune. What is the consensus analysts' recommendation for Oncimmune? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncimmune in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oncimmune. Has Oncimmune been receiving favorable news coverage? News articles about ONC stock have trended positive on Wednesday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Oncimmune earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. Who are some of Oncimmune's key competitors? Some companies that are related to Oncimmune include 3D Signatures (DXD), BioNano Genomics (BNGOU), Cambridge Cognition (COG), Carl Data Solutions (CRL), Carl Zeiss Meditec (AFX), Co-Diagnostics (CODX), Deepmatter Group (DMTR), EPIGENOMICS AG/S (EPGNY), Eternity Healthcare (ETAH), Genedrive (GDR), GeneNews (GEN), Imaging Dynamics (IDL), LED Medical Diagnostics (LMD), Lexagene (LXG) and MaxCyte (MXCT). Who are Oncimmune's key executives? Oncimmune's management team includes the folowing people: Mr. Adam Mark Hill Ph.D., CEO & Director (Age 38)Mr. Andrew Millet, CFO, Company Sec. & Exec. Director (Age 51)Dr. Laura J. Peek, Principal Scientist & Assistant Lab DirectorDr. Andrea Murray, Chief Operational ScientistDr. James Jett, Chief Medical Officer of US How do I buy shares of Oncimmune? Shares of ONC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Oncimmune's stock price today? One share of ONC stock can currently be purchased for approximately GBX 103. What is Oncimmune's official website? The official website for Oncimmune is http://oncimmune.com/. How can I contact Oncimmune? Oncimmune's mailing address is Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The company can be reached via phone at +44-115-8231869. MarketBeat Community Rating for Oncimmune (LON ONC)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 46 (Vote Outperform)Underperform Votes: 66 (Vote Underperform)Total Votes: 112MarketBeat's community ratings are surveys of what our community members think about Oncimmune and other stocks. Vote "Outperform" if you believe ONC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: Is a Roth IRA right for you?